HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target
Benzinga Newsdesk 4 months ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 price target.
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 price target.